Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43 by Lee, Hyun-Kyoung et al.
J OURNAL OF
Veterinary
Science Short Communication
J.  Vet.  Sci.  (2010),  11(2),    165򰠏167
DOI:  10.4142/jvs.2010.11.2.165
*Corresponding author
Tel: +82-2-880-1256; Fax: +82-2-880-1256
E-mail: pjhak@snu.ac.kr
Production of specific antibodies against SARS-coronavirus 
nucleocapsid protein without cross reactivity with human coronaviruses 
229E and OC43
Hyun-Kyoung Lee
1, Byoung-Hee Lee
2, Seung-Hyeok Seok
1, Min-Won Baek
1, Hui-Young Lee
1, Dong-Jae Kim
1, 
Yi-Rang Na
1, Kyoung-Jin Noh
1, Sung-Hoon Park
1, Dutta Noton Kumar
1, Hiroaki Kariwa
3, Mina Nakauchi
3, 
Suk-Jin Heo
4, Jae-Hak Park
1,*
1Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742, 
Korea
2Department of Animal Experimentation, College of Medicine, Seoul National University, Seoul 110-799, Korea
3Laboratory of Public Health, Department of Environmental Veterinary Sciences, Graduate School of Veterinary Medicine, 
Hokkaido University, Sapporo 060-0818, Japan
4Biological Diagnostic Products Team, Biologics Headquarters, Korea Food and Drug Administration, Seoul 122-704, Korea
  Severe acute respiratory syndrome (SARS) is a life-threatening 
disease for which accurate diagnosis is essential. Although 
many tools have been developed for the diagnosis of SARS, 
false-positive reactions in negative sera may occur because of 
cross-reactivity with other coronaviruses. We have raised 
polyclonal  and  monoclonal  antibodies  (Abs)  using  a 
recombinant form of the SARS virus nucleocapsid protein. 
Cross-reactivity  of  these  anti-SARS  Abs  against  human 
coronavirus (HCoV) 229E and HCoV OC43 were determined 
b y  W e s t e r n  b l o t t i n g .  T h e  A b s  p r o d u c e d  r e a c t e d  w i t h  
recombinant SARS virus nucleocapsid protein, but not with 
HCoV 229E or HCoV OC43.
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Severe acute respiratory syndrome (SARS) virus nucleocapsid 
(N) protein is abundantly released in the patients’ blood 
during early infection [6], which suggested that the N protein 
is a suitable candidate for diagnostic applications. Detection 
of specific circulating Abs is potentially a highly sensitive 
and specific way to diagnose SARS. However, detection of 
SARS Abs from early- infected patients is difficult, because 
most patients experience IgG seroconversion on average 20 
days after the onset of symptoms [5]. On the other hand, a 
highly conserved motif (FYYLGTGP: 111-118 a.a.), occurs 
in the N-terminal half of all coronavirus N proteins, and other 
conserved residues are reported to occur near this highly 
conserved motif [6]. The cross reactivity regions between 
SARS- coronavirus (CoV) and porcine CoVs were located 
in 120- 208 a.a. of N protein [12]. Cross-reactivity between 
SARS- CoV N protein and anti-human CoV (HCoV) 229E 
Abs or anti-HCov OC43 Abs has been reported [14]. It is 
therefore necessary to develop an assay that shows no 
cross-reactivity with other CoVs, especially HCoVs, to 
detect SARS proteins. Such a test could be used for early 
detection and follow-up of patients during treatment. In this 
study, we raised polyclonal and monoclonal Abs using a 
recombinant SARS N protein to develop a specific 
diagnostic test for SARS.
The cDNA of SARS-CoV strain Hanoi provided by Dr. 
Kariwa of Hokkaido University was used as a template for 
PCR by Accupower premix (Bioneer, Korea). The full length 
of the SARS-CoV N gene was inserted into vector pET21a 
(Novagen, German). After transformation, E. coli strain 
Origami B (DE3) pLysS competent cells were induced using 
1 mM IPTG (Invitrogen, USA) at 37
oC for 4 h. The expressed 
proteins were purified using the His-Bind kits (Novagen, 
German). Production of polyclonal and monoclonal Abs was 
performed as described by Shang et al. [7]. Human 
coronaviruses, HCoV 229E (ATCC, VR-730) and HCoV 
OC43 (ATCC, VR-1558), were infected to MRC-5 cells 
(Korean Cell Line Bank). Replication of these viruses was 
confirmed by RT-PCR of cell lysates infected with HCoV 
229E and HCoV OC43. RT-PCR was performed as described 
in a previous study [10]. To examine whether Abs against 
recombinant N protein of the SARS virus react with other 
HCoVs, we performed Western blotting on recombinant 
SARS N protein or cell lysates infected with HCoV 229E 
and HCoV OC43.166    Hyun-Kyoung Lee et al.
Fig. 1. RT-PCR of cell lysates infected with human coronavirus 
(HCoV) 229E and HCoV OC43. A: HCoV 229E specific RT- 
PCR, B: HCoV OC43 specific RT-PCR. The results of RT-PCR 
were consistent with virally infected MRC-5 cell. Lane M: 100 
bp DNA ladder, Lane MRC-5: normal MRC-5 cell lysates, Lane 
229E: HCoV 229E infected MRC-5 cell lysates, Lane OC43: 
HCoV OC43 infected MRC-5 cell lysates.
Fig. 2. Western blotting for detecting cross reactivity of polyclonal
antibody (Ab) and monoclonal Ab with HCoVs 229E and OC43.
A: SDS-PAGE, B: reacted with polyclonal Ab, C: reacted with 
monoclonal Ab. Purified recombinant N protein (Lanes N), HCoV
229E infected cell lysates (Lanes 229E) and HCoV OC43 infected
cell lysates (Lanes OC43) were run in SDS PAGE 12% gels with
molecular weight markers in Lane M.
In our previous study, the antigenicity of recombinant of 
SARS-CoV N protein was checked with a mouse anti- 
SARS-CoV N protein monoclonal IgG2a (Zymed, USA), 
and convalescent SARS serum provided by the National 
Institute of Hygiene and Epidemiology in Vietnam [4]. We 
selected polyclonal and monoclonal Abs that showed the 
highest reactivity with the N protein in an ELISA. With these 
Abs, we determined cross-reactivity against cell lysates infected 
with HCoV 229E and HCoV OC43 by Western blotting. The 
viruses in these cells lysates were confirmed by RT-PCR 
(Fig. 1). Abs reacted with recombinant N protein, but did not 
react with HCoVs in cell lysates (Fig. 2). To determine the 
specificity of these Abs, cross reactivity with porcine 
epidemic diarrhea virus (coronavirus group I) and mouse 
hepatitis virus (coronavirus group II) were analyzed by 
Western blotting but showed no reaction (data not shown).
Coronaviruses are a group of large, enveloped, positive- 
sense, single-stranded RNA viruses that are known to associate 
with respiratory, enteric and neurological diseases in humans Production of the antibodies specific to SARS-CoV nucleocapsid protein    167
and domestic animals [2]. Many researchers have reported 
cross-reactivity with other HCoV when the diagnostic systems 
are based on SARS N protein [9,14]. It is therefore important 
to explore the possibility of developing a diagnostic test for 
SARS-CoV that does not show this cross-reactivity with the 
other HCoVs. Only two coronaviruses, HCoV 229E (Group I) 
and HCoV OC43 (Group II), have previously been known to 
cause illness in humans [2]. These coronaviruses are responsible 
for 10∼35% of upper respiratory tract infections [9]. Another 
human coronaviruses, HCoV NL63 and Co HKU1, were reported 
in 2004 and 2005 [11,13]. As such, a SARS diagnostic system 
that cross-reacts with HCoVs could easily result in false-positive 
reactions. Previous researchers have tried to develop a monoclonal 
Ab against SARS N protein based ELISA. Some checked 
cross- reactivity with chicken CoV [3], HCoV OC43 [8] and 
various CoVs [1]. We need more Ab candidates for the diagnosis 
of SARS. In this study, we checked Abs cross-reactivity 
against SARS virus with HCoVs 229E and OC43, before 
developing a diagnostic system. Because the polyclonal and 
monoclonal Abs produced in this study did not react with 
HCoV 229E or HCoV OC43 in Western blotting, it could 
be possible to develop a specific diagnostic system to detect 
SARS-CoV in infected patients with theses Abs. Cross- 
reactivity with HCoV NL63 and Co HKU1, newly arising 
HCoVs, should be confirmed to strengthen the specificity 
of our Abs against SARS-CoV.
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